LOX

Across TCGA pan-cancer cohorts, LOX mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LOX data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LOX mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LOX expression acts as an unfavorable survival marker.

CCRCC, LUAD, and LSCC are the cancer types where LOX mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.605	0.861	<.001	73	view →
LUAD	OS	Median	All	0.579	0.848	.014	20	view →
LSCC	OS	Median	II,III,IV	0.904	1.000	.019	7	view →
PDAC	OS	Median	III,IV	0.471	1.000	.002	7	view →
HNSC	OS	Median	III,IV	0.598	0.775	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LOX–CCRCC (DFS)

Open the CCRCC breakdown →